Dr Reddy's Laboratories Ltd (NYSE:RDY)

69.90
Delayed Data
As of Nov 30
 +1.69 / +2.48%
Today’s Change
51.11
Today|||52-Week Range
73.17
+35.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$11.4B

Company Description

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Contact Information

Dr. Reddy's Laboratories Ltd.
Door No. 8-2-337
Hyderabad Telangana 500034
P:914049002900
Investor Relations:
914049002135

Employees

Shareholders

Mutual fund holders3.82%
Other institutional10.14%
Individual stakeholders--

Top Executives

Erez IsraeliChief Executive Officer
Parag AgarwalChief Financial Officer
B. PhanimitraChief Information Officer
Kumar Randhir SinghSecretary & Compliance Officer
M. V. RamanaCEO-India & Emerging Markets Branded Markets